Navigation Links
Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Date:11/29/2007

rial-scale production of recombinant therapeutic proteins. Protalix is enrolling and treating patients in its pivotal phase III clinical trial in Israel, the United States and other locations for its lead product candidate, prGCD, for its enzyme replacement therapy for Gaucher disease, a lysosomal storage disorder in humans, and has reached an agreement with the United States Food and Drug Administration on the final design of the pivotal phase III clinical trial through the FDA's Special Protocol Assessment (SPA) process. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.

Safe Harbor Statement:

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies and products under development, the identification of lead compounds, the successful preclinical development of our products, the completion of clinical trials, the review process of the FDA, foreign regulatory bodies and other governmental regulation, and other factors described in our filings with the Securities and Exchange Commission. The statements are valid only as of the date hereof and we disclaim any obligation to update this information.

For additional information, contact Protalix BioTherapeutics at: investors@protalix.com


'/>"/>
SOURCE Protalix BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Protalix BioTherapeutics to Present at UBS Global Life Sciences Conference
2. Protalix BioTherapeutics Announces Public Offering of Common Stock
3. Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock
4. Protalix BioTherapeutics to Present at CIBC World Markets 18th Annual Healthcare Conference
5. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
6. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
7. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
8. Globus Medical Announces Record 2nd Quarter 2007 Results
9. BioSpace Draws Record Crowd to Chicago Life Science Career Fair
10. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
11. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer health ... EmblemHealth , the New York -based ... RedBrick Compass health assessment, combined with the RedBrick Journeys ... EmblemHealth is among the first health plans in the ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched Sound ... Patients listen to sound therapy that is tailor-made for ... to months, their tinnitus volume decreases. , AudioNotch has previously ... Notched White Noise. Now, AudioNotch is pleased to announce to ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2DTS Improves Efficiency for Life Science Document Translations 2
... http://www.thirdbiotech.com ), a biotechnology incubator and life ... the ThirdBiotech Research,Group including a drug discovery ... of collaborative activities between researchers,and industry for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070911/LATU119LOGO ), "Over ...
... 25 The U.S. Food and Drug,Administration ... Drugs,voted to recommend the approval of tolvaptan, ... treatment,for patients with hyponatremia., "Otsuka is ... the,potential approval of tolvaptan, an investigational selective,V2-vasopressin ...
... is,strengthening its customer-focused biomarker services portfolio to,pharmaceutical, ... Xie will lead those efforts as Battelle,s ... a suite of biomarker services, including biomarker,discovery, ... clients,better define molecular mechanisms of diseases, toxicity, ...
Cached Biology Technology:ThirdBiotech Launches Research Institute to Promote Formation and Growth of Arizona-Based Biotech Companies 2U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia 2Battelle Selects Xie to Develop Biomarker Services 2
(Date:4/18/2014)... PROVIDENCE, R.I. [Brown University] Asteroid and comet impacts ... animals on regional or even global scales. But new ... preserve the signatures of ancient life at the time ... Brown geologist Pete Schultz has found fragments of leaves ... a several ancient impacts in Argentina. The material could ...
(Date:4/17/2014)... trials to treat tuberculosis could be the basis for ... bacteria, fungal infections and parasites, yet evade resistance, according ... collaborators. , Led by U. of I. chemistry professor ... drug SQ109 attacks the tuberculosis bacterium, how the drug ... to malaria and how targeting multiple pathways reduces ...
(Date:4/17/2014)... April 17, 2014The development of stem cell therapies to ... to characterize stem cell populations based on cell surface ... a new marker that is highly expressed in a ... blood, which they describe in an article in ... Ann Liebert, Inc., publishers. The article is available free ...
Breaking Biology News(10 mins):Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Multitarget TB drug could treat other diseases, evade resistance 2
... their native language of 1 and 0 absolutes but struggle ... While scientists are making slow, incremental progress in their quest ... body language, a more straightforward method of communication may help ... of researchers led by Charlie Kemp, director of the Center ...
... the equatorial Pacific long before Europeans arrived in the ... the way from modern-day Chile to western Mexico, according ... of Materials Science and Engineering. Details of ... years ago were reconstructed largely through the efforts of ...
... is a conspicuous and exaggerated display shaped by sexual ... attraction. At the level of the individual, song is ... Laiolo and colleagues at the Spanish Council of Research ... in north-eastern Spain and found an association between individual ...
Cached Biology News:Robot fetches objects with just a point and a click 2Robot fetches objects with just a point and a click 3Robot fetches objects with just a point and a click 4Floating a big idea: MIT demos ancient use of rafts to transport goods 2Floating a big idea: MIT demos ancient use of rafts to transport goods 3Floating a big idea: MIT demos ancient use of rafts to transport goods 4
... The University of New South Wales, Sydney, Australia ... Australia This is the Fourth Edition of this ... is a large format version (330 x ... 3rd edition. This product number includes the ...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
... The Jouan RC10 series of vacuum concentrators/centrifugal ... protection features allied to rapid and safe ... can be combined with oil-free or high ... and a wide selection of rotors (eliminating ...
Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
Biology Products: